7 results
An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess
Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.
Learn More
Children's Growth and Behavior Study
Researchers at the NIH Clinical Center are seeking healthy children for a study of growth and health behaviors. The purpose of the study is to better understand growth in children and adolescents.
Learn More
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus
People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.
Learn More